Screening for prostate cancer
RM Hoffman - New England Journal of Medicine, 2011 - Mass Medical Soc
New England Journal of Medicine, 2011•Mass Medical Soc
Key Clinical Points Prostate-Cancer Screening The introduction of prostate-specific antigen
(PSA) testing has nearly doubled the lifetime risk of receiving a diagnosis of prostate cancer.
A substantial proportion of PSA-detected cancers are considered overdiagnosed because
they would not cause clinical problems during a man's lifetime. Early results from two large,
randomized, controlled trials of screening were inconsistent; a European study showed a
modest decrease in prostate-cancer mortality, whereas a US study showed no decrease in …
(PSA) testing has nearly doubled the lifetime risk of receiving a diagnosis of prostate cancer.
A substantial proportion of PSA-detected cancers are considered overdiagnosed because
they would not cause clinical problems during a man's lifetime. Early results from two large,
randomized, controlled trials of screening were inconsistent; a European study showed a
modest decrease in prostate-cancer mortality, whereas a US study showed no decrease in …
Key Clinical Points
Prostate-Cancer Screening
- The introduction of prostate-specific antigen (PSA) testing has nearly doubled the lifetime risk of receiving a diagnosis of prostate cancer.
- A substantial proportion of PSA-detected cancers are considered overdiagnosed because they would not cause clinical problems during a man's lifetime.
- Early results from two large, randomized, controlled trials of screening were inconsistent; a European study showed a modest decrease in prostate-cancer mortality, whereas a U.S. study showed no decrease in prostate-cancer mortality.
- Treatments for prostate cancer can lead to complications, including urinary, sexual, and bowel dysfunction.
- Men considering prostate-cancer screening should be informed about the potential benefits and harms of screening and treatment.
The New England Journal Of Medicine